Blog Archives
CMT : when the NGS comes to both simplify and complicate things
Charcot-Marie-Tooth (or CMT) type hereditary sensory-motor neuropathies are clinically and genetically heterogeneous pathologies affecting all ages and all sexes. Relatively frequent in the general population, they have in common that they result in a variable scalability deficit in the muscles of limbs extremities (hands, feet) and sometimes very discreet sensory disorders. More than 80 genes … [Read more]
A study of genotype/phenotype discordance in the SMAs is very informative
SMA is a degenerative disease of the lower motor neurons, responsible for paralysis of varying severity. A distinction is made between four types (I to IV) depending on the age of onset of the deficit and the maximum motor ability achieved by the patient. In the large majority of cases, one identifies, in the patient, … [Read more]
Strengthening exercise can be beneficial for DMD patients in the medium term
Duchenne muscular dystrophy (DMD) is the most common myopathy in children. It results in a progressive muscle deficit predominantly at the root of the limbs and is accompanied by cardio-respiratory complications leading to death at an early age. According to an old dogma and based only on a few scientific studies in animals, physical exercise … [Read more]
A new form of mixed neuromuscular disease identified using molecular biology
The neuromuscular diseases consist of a group of pathologies that are heterogeneous, both clinically and aetiologically. The element they have in common is involvement of a constituent part of a motor unit. The boundary between purely myopathic disease and neuropathy is sometimes blurred, as demonstrated by the work of an international consortium of researchers in … [Read more]
Buprenorphine: a therapeutic alternative in paramyotonia congenita?
The paramyotonia congenita belongs to non-dystrophic myotonic syndromes. It is characterized by myotonia which paradoxically worsens during exercise and which can, if necessary, be disabling, especially in cold weather conditions. In the very large majority of cases, it is related to dominant mutations in the SNC4A gene encoding a voltage-gated sodium channel. Treatment remains symptomatic … [Read more]
Domagrozumab (PF-06252616) is not more efficacious than FKRP-related LGMDR9
While the anti-myostatin agents appear to be a tempting approach to restoring muscle in neuromuscular patients, of all the clinical trials in humans involving different drug molecules exercising this action (anti-myostatin antibodies, folliculin, drug molecules blocking or deceiving the myostatin receptors, etc.), none has demonstrated its efficacy, despite encouraging results in animal models, in particular … [Read more]
An overview of non-invasive ventilation in children with NMD
A significant number of neuromuscular diseases, foremost among them spinal muscular atrophy, Duchenne muscular dystrophy and certain congenital myopathies, are accompanied by restrictive respiratory disorders. Children suffering from these disorders are at-risk to develop hypoventilation, and possibly chest deformities. Over the years, non-invasive ventilation (NIV) stood out as an effective, and relatively easy to implement, … [Read more]
Systemic injection of an optimized antisense oligonucleotide into an FSH mouse model appears to be effective
Facioscapulohumeral dystrophy (FSH) is one of the most common myopathies. There are two forms, FSH1 and FSH2. In both cases, the DUX4 gene is abnormally expressed in the muscles. In an effort to inhibit DUX4, Canadian researchers have optimized antisense oligonucleotides by coupling them to a peptide that favors their penetration into muscle cells. This optimized … [Read more]
Pompe disease: a meta-analysis confirms the benefits of enzyme therapy in late-onset forms, but with more impact on walking than on breathing or muscle strength
Pompe disease (or Glycogen-storage disease type II) is a metabolic myopathy characterised by a deficiency of acid maltase or acid alpha-glucosidase, an enzyme that is necessary in glycogen degradation. The late-onset form of the disease (late-onset Pompe Disease or LOPD), although it has a better prognosis than the infant-onset form, can lead to highly incapacitating … [Read more]
The Institute is recruiting a Postdoctoral fellow (SMA) for the Centre for Research in Myology
The “Biotherapies for motor neuron disorders group” (BOND) is looking for a postdoctoral fellow to lead a research project on the understanding of novel molecular mechanisms involved in the Spinal Muscular Atrophy (SMA) pathogenesis. The project includes in vitro studies on mouse and human cell lines, analysis of human biopsies and in vivo tests on … [Read more]